Biotechnology company Pharming announced on Tuesday it has obtained a US patent to research new possibilities for its drug Rhucin in treating and protecting against injuries caused by ischemia and reperfusion.

Ischemia is a restriction in the blood supply caused by factors in blood vessels. Reperfusion occurs when the blood supply returns after a period of ischemia, causing tissue damage.
The patent, issued by the United States Patent and Trademark Office, is valid until 2028.
Pharming’s flagship drug Rhucin, better known here as Ruconest, is already on the market in several European countries for the treatment of swellings which may have fatal consequences.
Shares in Pharming rose at the news.